Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PASER vs NYDRAZID
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits cell wall synthesis in Mycobacterium tuberculosis by blocking mycolic acid synthesis. Also acts as a competitive inhibitor of folate synthesis.
Inhibits bacterial cell wall synthesis by blocking the incorporation of mycolic acid into the arabinogalactan layer, specific to mycobacteria.
Treatment of tuberculosis in combination with other antituberculosis drugs,Off-label: None
Treatment of active tuberculosis (in combination with other antituberculous agents),Prophylaxis of tuberculosis in high-risk individuals
4 g (8 capsules of 500 mg) orally every 8 hours, taken with food or an acidic beverage (e.g., orange juice) to enhance absorption.
300 mg orally once daily; alternatively, 5 mg/kg (max 300 mg) orally once daily for 6-9 months for latent tuberculosis; for active tuberculosis, 5 mg/kg (max 300 mg) orally once daily for 2 months followed by 3 times weekly dosing (15 mg/kg, max 900 mg) for 4-7 months.
Terminal elimination half-life is 1.5 to 2.5 hours in patients with normal renal function. In anuria or severe renal impairment (Cr Cl <10 m L/min), half-life may extend to 8-12 hours. Clinical context: Accumulation occurs with renal failure, requiring dose adjustment.
Terminal elimination half-life: 1-4 hours (fast acetylators), 2-8 hours (slow acetylators). Half-life prolonged in hepatic impairment; adjust dose.
Hepatic via N-acetyltransferase (polymorphic acetylation); major metabolite is acetyl-PAS.
Hepatic metabolism primarily via N-acetyltransferase 2 (NAT2) to acetylisoniazid, which is further metabolized to hepatotoxic metabolites.
Renal excretion accounts for approximately 80% of the administered dose, with about 60-70% as unchanged drug and 10-20% as metabolites (primarily acetylated). The remainder is excreted via feces (approximately 10-15%) and minor biliary elimination. Renal clearance is highly dependent on glomerular filtration rate.
Renal excretion of unchanged drug and metabolites; 50-70% excreted in urine within 24 hours, mainly as acetylisoniazid and isonicotinic acid. Biliary/fecal: <10%.
Protein binding is approximately 10-15%, primarily to albumin. Binding is low, nonlinear, and saturable at high concentrations.
10-20% bound primarily to albumin; binding is low and clinically insignificant.
Volume of distribution is 0.5-0.7 L/kg, indicating distribution into total body water. Clinical meaning: Moderate distribution suggests penetration into well-perfused tissues but limited CNS penetration unless inflamed.
Vd: 0.6-0.8 L/kg; distributes into total body water, including CSF, pleural fluid, and caseous granulomas.
Oral bioavailability is approximately 70-80% (range 60-90%). Food decreases the rate and extent of absorption, with AUC reduction of about 20-40%.
Oral: 90-100% (fasting). Food may decrease absorption by 20-50%; take on empty stomach.
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). For Cr Cl 30-50 m L/min: reduce dose to 4 g orally every 12 hours; monitor serum concentrations. Use with caution in moderate impairment.
If GFR < 30 m L/min: administer 200 mg once daily or 300 mg three times weekly. For severe renal impairment (GFR < 10 m L/min) or hemodialysis: 200 mg daily or 300 mg three times weekly, given after dialysis.
No specific dose adjustment guidelines for Child-Pugh classification. Use with caution in severe hepatic impairment due to potential hepatotoxicity; monitor liver function tests.
Child-Pugh Class A: no adjustment needed. Child-Pugh Class B: reduce dose by 50% (e.g., 150 mg daily). Child-Pugh Class C: reduce dose by 50-75% (e.g., 100-150 mg daily) or consider alternative therapy; monitor liver function closely.
Not recommended for children (safety and efficacy not established).
For latent tuberculosis: 10-15 mg/kg (max 300 mg) orally once daily for 6-9 months. For active tuberculosis: 10-15 mg/kg (max 300 mg) orally once daily for 2 months, then 15 mg/kg (max 900 mg) orally three times weekly for 4-7 months.
Lower initial doses may be considered due to age-related decline in renal function. Monitor renal function and serum concentrations closely.
Start at lower end of dosing range (e.g., 200-300 mg daily) due to potential renal impairment; monitor liver function and signs of hepatotoxicity; adjust dose based on creatinine clearance if GFR < 30 m L/min.
None
Severe and sometimes fatal hepatitis has been reported, even after months of treatment. Risk increases with age, daily alcohol use, and pre-existing liver disease. Monitor liver function tests closely.
May cause hypothyroidism, hepatitis, and crystalluria. Use with caution in patients with renal impairment or glucose-6-phosphate dehydrogenase deficiency.
Peripheral neuropathy (prevent with pyridoxine), hepatotoxicity, hypersensitivity reactions (e.g., fever, rash), lupus-like syndrome, seizures, optic neuritis, drug interactions (e.g., phenytoin, carbamazepine, disulfiram).
Hypersensitivity to para-aminosalicylic acid or any component; severe renal impairment.
Severe hepatic disease, acute liver disease, or previous isoniazid-associated hepatitis; hypersensitivity to isoniazid or any component.
Take with food to reduce gastrointestinal irritation. Avoid high-fat meals as they may delay absorption. Avoid alcohol.
Isoniazid inhibits monoamine oxidase (MAO) and reduces metabolism of tyramine, leading to hypertensive crisis. Avoid tyramine-rich foods: aged cheeses (cheddar, blue cheese), cured or fermented meats (salami, pepperoni, pickled herring), soy products (tofu, miso, tempeh), sauerkraut, fava beans, tap beers, and red wines. Also avoid foods containing histamine (tuna, mackerel, sauerkraut). Concomitant alcohol consumption increases risk of hepatotoxicity and should be strictly avoided. High-protein meals or dairy may interfere with absorption; maintain consistent timing relative to meals. There is no restriction on carbohydrates or fats.
PASER (aminosalicylic acid) is classified FDA pregnancy category C. First trimester: Limited human data; animal studies show no teratogenicity but some fetal toxicity at high doses. Second and third trimesters: No known major malformations; risks may include gastrointestinal intolerance in mother. Advised use only if clearly needed.
Isoniazid (INH) is not associated with major congenital malformations in humans. However, in vivo animal studies have shown embryocidal effects at high doses. The drug is considered safe during all trimesters; however, due to the risk of hepatotoxicity, monitoring of liver function is recommended, especially in the third trimester. Perinatal exposure increases the risk of neonatal hemorrhage due to vitamin K deficiency, which can be prevented by prophylactic vitamin K administration to the mother.
Excreted into breast milk in small amounts. M/P ratio unknown. Considered compatible with breastfeeding by American Academy of Pediatrics; monitor infant for diarrhea or rash.
Isoniazid is excreted into breast milk in concentrations similar to maternal plasma. The milk-to-plasma (M/P) ratio is approximately 1.0. The American Academy of Pediatrics considers it compatible with breastfeeding. However, due to the theoretical risk of hepatotoxicity and peripheral neuropathy in the infant, monitoring of the infant for signs of jaundice, hepatitis, or neuropathy is recommended. The dose to the infant is subtherapeutic (about 0.5-2% of the maternal dose) and is unlikely to cause adverse effects.
No dosing adjustment required for pregnancy. Pharmacokinetic changes in pregnancy (increased clearance) not significant for PASER; standard adult dose of 4 g twice daily is recommended.
Standard dosing of isoniazid (300 mg daily or 900 mg twice weekly) is generally recommended during pregnancy. No dose adjustment is required as pregnancy does not significantly alter the pharmacokinetics of isoniazid. However, due to increased hepatic metabolism in pregnancy, some experts recommend monitoring serum drug levels to ensure therapeutic concentrations, though routine monitoring is not standard. Pyridoxine (25-50 mg daily) should be co-administered to prevent peripheral neuropathy in the mother and fetus.
PASER (aminosalicylic acid) is a second-line antitubercular agent that inhibits folic acid synthesis. Administer with food to reduce GI upset; avoid concurrent use with salicylates due to additive GI irritation. Monitor for hepatotoxicity and hypersensitivity reactions. Drug levels should be monitored in patients with renal impairment.
NYDRAZID (isoniazid) is a first-line antitubercular agent. Always prescribe pyridoxine (vitamin B6) 25-50 mg daily to prevent peripheral neuropathy, especially in patients with risk factors like diabetes, alcoholism, malnutrition, or HIV. Monitor liver function tests closely; hepatotoxicity risk increases with age >35, concurrent use of acetaminophen or other hepatotoxic drugs, and pre-existing liver disease. Slow acetylators (genetic) have higher risk of toxicity. Isoniazid can cause bilateral optic neuritis; monitor for visual symptoms. Drug interactions: increases levels of phenytoin, carbamazepine, and theophylline; reduce doses accordingly. Administer on empty stomach (1 hour before or 2 hours after meals) for optimal absorption. In case of overdose, high-dose pyridoxine is antidote (1 g per gram of isoniazid ingested).
Take this medication with food to minimize stomach upset.,Do not crush or chew the tablets; swallow them whole.,Complete the full course of therapy even if you feel better.,Report any signs of liver problems (yellowing of skin/eyes, dark urine) or allergic reactions (rash, fever) immediately.,Avoid alcohol during treatment.,Store at room temperature away from moisture and heat.
Take isoniazid on an empty stomach with a full glass of water, at least 1 hour before or 2 hours after meals.,Do not drink alcohol while taking this medication; combined with alcohol increases risk of severe liver damage.,Take vitamin B6 (pyridoxine) exactly as prescribed to prevent nerve damage.,Report immediately: dark urine, pale stools, yellowing of skin or eyes, nausea/vomiting, abdominal pain, unusual fatigue (liver toxicity signs).,Report numbness, tingling, or burning in hands/feet; vision changes; rash; or fever.,Avoid foods high in tyramine (aged cheese, cured meats, soy products, tap beer) while taking isoniazid; may cause hypertensive crisis.,Take all doses on schedule; do not skip or stop without consulting provider.,Keep all follow-up appointments for blood tests to monitor liver function.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PASER vs NYDRAZID, answered by our medical review team.
PASER is a Antitubercular Agent that works by Inhibits cell wall synthesis in Mycobacterium tuberculosis by blocking mycolic acid synthesis. Also acts as a competitive inhibitor of folate synthesis.. NYDRAZID is a Antitubercular Agent that works by Inhibits bacterial cell wall synthesis by blocking the incorporation of mycolic acid into the arabinogalactan layer, specific to mycobacteria.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PASER and NYDRAZID depend on the specific clinical indication. These are both Antitubercular Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PASER is: 4 g (8 capsules of 500 mg) orally every 8 hours, taken with food or an acidic beverage (e.g., orange juice) to enhance absorption.. The standard adult dose of NYDRAZID is: 300 mg orally once daily; alternatively, 5 mg/kg (max 300 mg) orally once daily for 6-9 months for latent tuberculosis; for active tuberculosis, 5 mg/kg (max 300 mg) orally once daily for 2 months followed by 3 times weekly dosing (15 mg/kg, max 900 mg) for 4-7 months.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PASER and NYDRAZID in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PASER is classified as Category C. PASER (aminosalicylic acid) is classified FDA pregnancy category C. First trimester: Limited human data; animal studies show no teratogenicity but some fetal toxicity at high doses. NYDRAZID is classified as Category C. Isoniazid (INH) is not associated with major congenital malformations in humans. However, in vivo animal studies have shown embryocidal effects at high doses. The drug is considere. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.